Continuous venovenous hemofiltration with citrate-based replacement fluid: efficacy, safety, and impact on nutrition
- PMID: 16253732
- DOI: 10.1053/j.ajkd.2005.08.010
Continuous venovenous hemofiltration with citrate-based replacement fluid: efficacy, safety, and impact on nutrition
Abstract
Background: Citrate-based continuous venovenous hemofiltration (CVVH) replacement fluids provide effective and simple regional anticoagulation. However, concern over toxicity has limited citrate use, especially at the high filtration rates advocated for better outcomes. We used volumes of 72 L/d in patients at high risk for bleeding and investigated the treatment's efficacy, safety, and clinical results, especially with regard to nutrition supplementation.
Methods: A standard replacement solution (trisodium citrate, 13.3 mmol/L) was infused at up to 3 L/h in predilution CVVH, and ultrafiltration was increased further for net fluid removal. Calcium was repleted centrally. We retrospectively evaluated metabolic control, citrate toxicity, circuit patency, hemorrhagic complications, hemodynamics, vasopressor use, nutrition, renal recovery, and mortality.
Results: Seventy-six patients with 766 CVVH patient-days were analyzed. Mean replacement fluid rate was 31 mL/kg/h (35 mmol/h of citrate), with hemofiltration of 35 mL/kg/h (67 +/- 11 L/d). No significant bleeding, citrate toxicity, or hypocalcemia was observed, and 74% required additional alkali therapy. Dialyzer patency was 58% at 48 hours. Control of fluid, electrolytes, and azotemia was excellent (serum creatinine level, 1.7 mg/dL [150 micromol/L]; blood urea nitrogen, 42 mg/dL [15 mmol/L]). Fluid removal permitted protein (1.7 g/kg/d) and calorie (30 kcal/kg/d) nutrition in high fluid volumes. Vasopressor use and central pressures decreased significantly. Cumulative 28-day intensive care unit survival was 58%, and 41% of these patients had renal recovery in the intensive care unit. Thirty percent of the entire cohort survived the hospitalization, and 53% of these patients recovered renal function.
Conclusion: CVVH with 3 L/h of citrate-based replacement fluid is a safe, efficient, and simple technique in patients at high risk for bleeding. It allows superb control of uremia and fluid balance and thereby permits aggressive nutritional support.
Comment in
-
Citrate-based replacement solutions with continuous venovenous hemofiltration: not as simple as it sounds.Am J Kidney Dis. 2006 Jun;47(6):1086; author reply 1086-7. doi: 10.1053/j.ajkd.2006.03.080. Am J Kidney Dis. 2006. PMID: 16731311 No abstract available.
Similar articles
-
Citrate clearance in children receiving continuous venovenous renal replacement therapy.Pediatr Nephrol. 2002 Oct;17(10):819-24. doi: 10.1007/s00467-002-0963-6. Epub 2002 Sep 7. Pediatr Nephrol. 2002. PMID: 12376810 Clinical Trial.
-
Regional citrate anticoagulation using a citrate-based substitution solution for continuous venovenous hemofiltration in cardiac surgery patients.Wien Klin Wochenschr. 2002 Feb 15;114(3):108-14. Wien Klin Wochenschr. 2002. PMID: 12060967
-
Regional citrate anticoagulation for intermittent predilution online hemofiltration.Ther Apher Dial. 2009 Aug;13(4):306-9. doi: 10.1111/j.1744-9987.2009.00729.x. Ther Apher Dial. 2009. PMID: 19695064
-
Citrate anticoagulation for continuous renal replacement therapy in the critically ill.Blood Purif. 2010;29(2):191-6. doi: 10.1159/000245646. Epub 2010 Jan 8. Blood Purif. 2010. PMID: 20093826 Review.
-
Automated regional citrate anticoagulation: technological barriers and possible solutions.Blood Purif. 2010;29(2):204-9. doi: 10.1159/000245648. Epub 2010 Jan 8. Blood Purif. 2010. PMID: 20093828 Review.
Cited by
-
Intensity of continuous renal replacement therapy for acute kidney injury.Cochrane Database Syst Rev. 2016 Oct 4;10(10):CD010613. doi: 10.1002/14651858.CD010613.pub2. Cochrane Database Syst Rev. 2016. PMID: 27699760 Free PMC article.
-
Metabolic Strategies for Inhibiting Cancer Development.Adv Nutr. 2021 Jul 30;12(4):1461-1480. doi: 10.1093/advances/nmaa174. Adv Nutr. 2021. PMID: 33530098 Free PMC article. Review.
-
A mode of CVVH with regional citrate anticoagulation compared to no anticoagulation for acute kidney injury patients at high risk of bleeding.Sci Rep. 2019 Apr 29;9(1):6607. doi: 10.1038/s41598-019-42916-1. Sci Rep. 2019. PMID: 31036927 Free PMC article.
-
Clinical review: Patency of the circuit in continuous renal replacement therapy.Crit Care. 2007;11(4):218. doi: 10.1186/cc5937. Crit Care. 2007. PMID: 17634148 Free PMC article. Review.
-
Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution.Crit Care. 2012 Jun 27;16(3):R111. doi: 10.1186/cc11403. Crit Care. 2012. PMID: 22738289 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials